



(12) Translation of
European patent specification

(11) NO/EP 2970255 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 471/04 (2006.01)
A61K 31/437 (2006.01)
A61P 9/00 (2006.01)
A61P 11/00 (2006.01)
A61P 25/28 (2006.01)
A61P 29/00 (2006.01)
A61P 35/00 (2006.01)
A61P 37/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2017.11.06
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.08.02
(86)	European Application Nr.	14708291.1
(86)	European Filing Date	2014.03.07
(87)	The European Application's Publication Date	2016.01.20
(30)	Priority	2013.03.14, US, 201361781174 P
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:	BA ME
(73)	Proprietor	Galapagos NV, Generaal De Wittelaan L11/A3, 2800 Mechelen, BE-Belgia
(72)	Inventor	DESROY, Nicolas, 102 Avenue Gaston Roussel, F-93230 Romainville, FR-Frankrike HECKMANN, Bertrand, 102 Avenue Gaston Roussel, F-93230 Romainville, FR-Frankrike BRYS, Reginald Christophe Xavier, Generaal De Wittelaan L11/A3, B-2800 Mechelen, BE-Belgia JONCOUR, Agnès, 102 Avenue Gaston Roussel, F-93230 Romainville, FR-Frankrike PEIXOTO, Christophe, 102 Avenue Gaston Roussel, F-93230 Romainville, FR-Frankrike BOCK, Xavier, 102 Avenue Gaston Roussel, F-93230 Romainville, FR-Frankrike
(74)	Agent or Attorney	Bryn Aarflot AS, Postboks 449 Sentrum, 0104 OSLO, Norge

(54) Title **COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS**


(56) References Cited: WO-A1-2012/166415

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse med formel I:

5



hvor

 R^{1a} er H, halogen eller C_{1-4} alkyl;10 R^{1b} er:

- halogen,
- C_{1-4} alkyl (hvor alkyl eventuelt er substituert med ett eller flere uavhengig valgte halogener), eller
- C_{1-4} alkoxsy (hvor alkoxsy eventuelt er substituert med ett eller flere uavhengig valgte halogener);

 X er $-S-$, $-O-$, $-N=CH-$, $-CH=N-$ eller $-CH=CH-$; W er N eller CR^3 når W er N, da er R^2 :

- H,
- $-CN$,
- halogen,
- C_{1-4} alkyl (hvor alkyl eventuelt er substituert med én eller flere uavhengig valgte OH eller CN)
- $-C(=O)CH_3$,

25 - $-C(=O)CF_3$,- $-C(=O)OCH_3$,- $-C(=O)NH_2$, eller- $-NHC(=O)CH_3$, ellernår W er CR^3 , er én av R^2 eller R^3 :

30 - H,

- $-CN$,

- halogen,
 - C₁₋₄ alkyl (hvor alkyl eventuelt er substituert med én eller flere uavhengig valgte OH eller CN)

- -C(=O)CH₃,

5 - -C(=O)CF₃,

- -C(=O)OCH₃,

- -C(=O)NH₂,

- -NHC(=O)CH₃,

og den andre er H eller C₁₋₄ alkyl;

10 R⁴ er C₁₋₄ alkyl;

R⁵ er C₁₋₄ alkyl eventuelt substituert med én eller flere uavhengig valgte CN, OH, halogen eller -C(=O)NH₂;

én av R^{6a} eller R^{6b} er valgt fra H, -CH₃ og halogen og den andre er H;

Cy er:

15 - C₄₋₁₀ cykloalkyl,

- 4-10 leddet mono- eller bacyklisk heterocykloalkyl inneholdende ett eller flere heteroatomer uavhengig valgt fra O, N og S, eller
 - 4-7 leddet heterocykloalkenyl inneholdende 1 dobbeltbinding, inneholdende ett eller flere heteroatomer uavhengig valgt fra O, N og S;

20 hver R⁷ er uavhengig valgt fra:

- OH,

- okso,

- halogen, og

- C₁₋₄ alkyl (hvor alkyl eventuelt er substituert med én eller flere uavhengig valgte OH eller C₁₋₄ alkoks);

25 indeksen a er 0, 1 eller 2;

R⁸ er -(L₁-W₁)_m-L₂-G₁,

hvor

- L₁ er fraværende eller er -O-, -C(=O)-, -NRⁱ, -NR^hC(=O)- eller -SO₂-;

30 - W₁ er C₁₋₄ alkylen;

- indeksen m er 0 eller 1;


- L₂ er fraværende eller er -O-, -C(=O)-, -C(=O)O-, -OC(=O)-, -C(=O)-C(=O)-, -C(=O)-C(=O)NR^a-, -NR^b-, -C(=O)NR^c-, -NR^dC(=O)-, -NR^jC(=O)O-, -SO₂-, -SO₂NR^e- eller -NR^fSO₂-;

35 - G₁ er

◦ H,

◦ -CN,


- C₁₋₄ alkyl (hvor alkyl eventuelt er substituert med én eller flere uavhengig valgte -CN, OH, halogen eller fenyl),
 - C₃₋₇ cykloalkyl (hvor cykloalkyl eventuelt er substituert med -NH₂),
 - 5-6 ledet heterocykloalkenyl inneholdende 1 dobbeltbinding inneholdende ett eller flere heteroatomer uavhengig valgt fra O, N og S (hvor heterocykloalkenyl eventuelt er substituert med én eller flere uavhengig valgte R⁹ grupper),
 - 4-10 ledet mono, bi eller spirocyklisk heterocykloalkyl inneholdende ett eller flere heteroatomer uavhengig valgt fra O, N og S (hvor heterocykloalkyl eventuelt er substituert med én eller flere uavhengig valgte R⁹ grupper), eller
 - 5-6 ledet heteroaryl inneholdende ett eller flere heteroatomer uavhengig valgt fra O, N og S (hvor heteroaryl eventuelt er substituert med én eller flere uavhengig valgte R¹⁰ grupper),
- hver R⁹ er okso eller R¹⁰;
- hver R¹⁰ er:
- -OH,
 - halogen,
 - -CN,
 - C₁₋₄ alkyl (hvor alkyl eventuelt er substituert med én eller flere uavhengig valgte OH, halogen eller fenyl),
 - C₁₋₄ alkoksy,
 - C₃₋₇ cykloalkyl,
 - fenyl,
 - -SO₂CH₃,
 - -C(=O)C₁₋₄ alkoksy,
 - -C(=O)C₁₋₄ alkyl, eller
 - -NR⁹C(=O)C₁₋₄ alkyl; og
- hver R^a, R^b, R^c, R^d, R^e, R^f, R^g, R^h, Rⁱ og R^j uavhengig er valgt fra H og C₁₋₄ alkyl; eller et farmasøytisk akseptabelt salt eller et solvat eller et farmasøytisk akseptabelt salt av et solvat derav.
2. Forbindelse eller farmasøytisk akseptabelt salt derav ifølge krav 1, hvor forbindelsen ikke er en isotopisk variant.
3. Forbindelse eller farmasøytisk akseptabelt salt derav ifølge krav 1 eller 2, hvor forbindelsen er i henhold til Formel II:



hvor Cy, R⁴, R⁵, R^{6a}, R^{6b}, R⁷, R⁸ og indeksen a er ifølge krav 1.

5

4. Forbindelse eller farmasøytisk akseptabelt salt derav ifølge krav 1 eller 2, hvor forbindelsen er i henhold til Formel III:



10

hvor Cy, R⁴, R⁵, R^{6a}, R^{6b}, R⁷, R⁸ og indeksen a er ifølge krav 1.

5. Forbindelse eller farmasøytisk akseptabelt salt derav ifølge hvilket som helst av kravene 1-4, hvor R⁵ er -CH₃ eller -C₂H₅.

15

6. Forbindelse eller farmasøytisk akseptabelt salt derav ifølge krav 4, hvor R⁵ er -CH₂-CH₂-CN, -CH₂-CH₂-OH, -CH₂-CF₃ eller -CH₂-CH₂-C(=O)NH₂.


20

7. Forbindelse eller farmasøytisk akseptabelt salt derav ifølge hvilket som helst av kravene 1-6, hvor Cy er 4-10 leddet mono- eller bacyklisk heterocykloalkyl inneholdende ett eller flere heteroatomer uavhengig valgt fra O, N og S.


8. Forbindelse eller farmasøytisk akseptabelt salt derav ifølge hvilket som helst av kravene 1-7, hvor indeksen a er 0.

25

9. Forbindelse ifølge krav 1 eller 2, hvor forbindelsen er i henhold til Formel Va, Vb, Vc eller Vd:




Va,




Vb,

5



Vc, or



Vd

hvor R^{6a} , R^{6b} , W_1 og G_1 er ifølge krav 1.

- 10 10. Forbindelse eller farmasøytsk akseptabelt salt derav ifølge krav 9, hvor W_1 er - CH_2- , - CH_2-CH_2- , - $C(CH_3)H-$, - $CH_2-CH_2-CH_2-$ eller - $CH_2-C(CH_3)H-$.
11. Forbindelse eller farmasøytsk akseptabelt salt derav ifølge hvilket som helst av kravene 9-10, hvor G_1 er 4-7 ledet heterocykloalkyl inneholdende ett eller flere heteroatomer uavhengig valgt fra O, N og S, hvor heterocykloalkyl er substituert med én eller to uavhengig valgte R^9 grupper.
12. Forbindelse eller farmasøytsk akseptabelt salt derav ifølge krav 11, hvor R^9 er R^{10} og R^{10} er valgt fra OH, F, Cl og -CN.
- 20 13. Forbindelse eller farmasøytsk akseptabelt salt derav ifølge hvilket som helst av kravene 1-12, hvor R^{6a} er H, - CH_3 eller F og R^{6b} er H.
- 25 14. Forbindelse eller farmasøytsk akseptabelt salt derav ifølge krav 1 eller 2, hvor forbindelsen er valgt fra:

2-((2-ethyl-8-metyl-6-(piperazin-1-yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-karbonitril,
2-((2-ethyl-6-(4-(2-(3-hydroksyazetidin-1-yl)-2-oksoetyl)piperazin-1-yl)-8-metylimidazo[1,2-a]pyridin-3-yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-karbonitril,
5 2-((2-ethyl-6-(4-(2-(3-hydroksy-3-metylazetidin-1-yl)-2-oksoetyl)piperazin-1-yl)-8-metylimidazo[1,2-a]pyridin-3-yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-karbonitril,
(R)-2-((2-ethyl-6-(4-(2-(3-hydroksyazetidin-1-yl)-2-oksoetyl)piperazin-1-yl)-8-metylimidazo[1,2-a]pyridin-3-yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-karbonitril,
(S)-2-((2-ethyl-6-(4-(2-(3-hydroksyazetidin-1-yl)-2-oksoetyl)piperazin-1-yl)-8-metylimidazo[1,2-a]pyridin-3-yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-karbonitril,
10 2-((2-ethyl-6-(4-(2-(3-hydroksyazetidin-1-yl)-2-oksoetyl)-3,3-dimethylpiperazin-1-yl)-8-metylimidazo[1,2-a]pyridin-3-yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-karbonitril,
2-((4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)-8-metylimidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-1-(3-hydroksyazetidin-1-yl)etanon,
15 (R)-2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)-8-metylimidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-1-(3-hydroksyazetidin-1-yl)etanon,
(S)-2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)-8-metylimidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-1-(3-hydroksyazetidin-1-yl)etanon,
2-((2-ethyl-6-(1-(2-(3-hydroksyazetidin-1-yl)-2-oksoetyl)piperidin-4-yl)-8-metylimidazo[1,2-a]pyridin-3-yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-karbonitril,
20 2-(ethyl(2-ethyl-8-metyl-6-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)imidazo[1,2-a]pyridin-3-yl)amino)-4-(4-fluorfenyl)tiazol-5-karbonitril,
2-((2-ethyl-8-fluor-6-(4-(2-(3-hydroksyazetidin-1-yl)-2-oksoetyl)piperazin-1-yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-karbonitril,
25 2-(4-(3-((5-cyano-4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)-2-ethyl-8-fluorimidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-N-metylacetamid,
2-(4-(2-ethyl-8-fluor-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-1-(3-hydroksyazetidin-1-yl)etanon,
30 (S)-2-(4-(2-ethyl-8-fluor-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-1-(3-hydroksyazetidin-1-yl)etanon,
(R)-2-(4-(2-ethyl-8-fluor-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-1-(3-hydroksyazetidin-1-yl)etanon,
2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)-7-metylimidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)-1-(3-hydroksyazetidin-1-yl)etanon,
35 2-[(2-ethyl-7-fluor-6-{4-[2-(3-hydroksyazetidin-1-yl)-2-okso-etyl]-piperazin-1-yl}-imidazo[1,2-a]pyridin-3-yl)-methyl-amino]-4-(4-fluor-fenyl)-tiazol-5-karbonitril,

2-[4-(2-ethyl-7-fluor-3-{[4-(4-fluor-fenyl)-tiazol-2-yl]-methyl-amino}-imidazo[1,2-a]pyridin-6-yl)-piperazin-1-yl]-1-(3-hydroksy-azetidin-1-yl)-etanon,
2-[4-(2-ethyl-7-fluor-3-{[4-(4-fluor-fenyl)-tiazol-2-yl]-methyl-amino}-imidazo[1,2-a]pyridin-6-yl)-piperazin-1-yl]-1-(3-hydroksy-pyrrolidin-1-yl)-etanon,
5 2-[4-(2-ethyl-7-fluor-3-{[4-(4-fluor-fenyl)-tiazol-2-yl]-methyl-amino}-imidazo[1,2-a]pyridin-6-yl)-piperazin-1-yl]-1-(3-hydroksy-pyrrolidin-1-yl)-etanon,
2-(4-(3-((5-cyano-4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)-2-etyl)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-N-metylacetamid,
tert-butyl 4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-karboksylat,
2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-1-(3-hydroksyazetidin-1-yl)etanon,
(S)-2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-1-(3-hydroksypyrrolidin-1-yl)etanon,
15 (R)-2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-1-(3-hydroksypyrrolidin-1-yl)etanon,
N-(1-(2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)acetyl)pyrrolidin-3-yl)acetamid,
2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-1-(3-fluorazetidin-1-yl)etanon,
20 1-(3,3-difluorazetidin-1-yl)-2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)etanon,
1-(azetidin-1-yl)-2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)etanon,
25 2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-1-(pyrrolidin-1-yl)etanon,
2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-1-morfolinoetanon,
2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-
30 yl)piperazin-1-yl)acetamid,
2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-1-(3-(hydroksymethyl)azetidin-1-yl)etanon,
2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-
35 yl)piperazin-1-yl)-N,N-dimetylacetamid,
ethyl 2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)acetat,

etyl 2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)propanoat,
2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)acetonitril,
5 N-(6-(4-((1-cyklopropyl-1H-tetrazol-5-yl)metyl)piperazin-1-yl)-2-etylimidazo[1,2-a]pyridin-3 - yl)-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,
N-(2-ethyl-6-(4-(oksazol-2-ylmetyl)piperazin-1-yl)imidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,
N-(6-(4-((1,2,4-oksadiazol-3-yl)metyl)piperazin-1-yl)-2-etylimidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,
10 2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)eddiksyre,
2-hydroksyethyl 4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-karboksylat,
15 tert-butyl 2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-karbonyl)pyrrolidin-1-karboksylat,
tert-butyl 3-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-karbonyl)pyrrolidin-1-karboksylat,
a (4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-
20 yl)piperazin-1-yl)(pyrrolidin-2-yl)metanon,
(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)(pyrrolidin-3-yl)metanon,
1-(3-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-
yl)piperazin-1-karbonyl)pyrrolidin-1-yl)etanon,
25 (4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)(1-(methylsulfonyl)pyrrolidin-3-yl)metanon,
1-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-2-hydroksyetanon,
1-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-
30 yl)piperazin-1-yl)propan-1-on,
1-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-4-hydroksybutan-1-on,
4-(dimethylamino)-1-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)-
imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)butan-1-on,
35 N-(2-ethyl-6-(4-(methylsulfonyl)piperazin-1-yl)imidazo [1,2-a]pyridin-3-yl)-4-(4-
fluorfenyl)-N-metyltaiazol-2-amin,

N-(6-(4-(3-klorpropylsulfonyl)piperazin-1-yl)-2-etylimidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltiazol-2-amin,
N-(6-(4-(3-(dimethylamino)propylsulfonyl)piperazin-1-yl)-2-etylimidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltiazol-2-amin,
5 N-(2-etyl-6-(4-(3-(pyrrolidin-1-yl)propylsulfonyl)piperazin-1-yl)imidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltiazol-2-amin,
3-(4-(2-etyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-ylsulfonyl)propan-1-ol,
metyl 2-(4-(2-etyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-ylsulfonyl)acetat,
10 2-(4-(2-etyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-ylsulfonyl)eddiksyre,
2-(4-(2-etyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-ylsulfonyl)acetamid,
15 tert-butyl 4-(2-etyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)-3-oksopiperazin-1-karboksylat,
tert-butyl 4-(3-((4-(4-klorfenyl)tiazol-2-yl)(metyl)amino)-2-etylimidazo[1,2-a]pyridin-6-yl)-3-oksopiperazin-1-karboksylat,
etyl 2-(4-(2-etyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-
20 yl)-3-oksopiperazin-1-yl)acetat,
1-(2-etyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)-4-(methylsulfonyl)piperazin-2-on,
N-(2-etyl-6-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)imidazo[1,2-a]pyridin-3-
yl)-4-(4-fluorfenyl)-N-metyltiazol-2-amin,
25 N-(6-(1-(klormethylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-2-etylimidazo[1,2-a]pyridin-3-
yl)-4-(4-fluorfenyl)-N-metyltiazol-2-amin,
4-(4-klorfenyl)-N-(2-etyl-6-(1-(methylsulfonyl)-2,5-dihydro-1H-pyrrol-3-
yl)imidazo[1,2-a]pyridin-3-yl)-N-metyltiazol-2-amin,
4-(4-klorfenyl)-N-(2-etyl-6-(1-(methylsulfonyl)-1,4,5,6-tetrahydropyridin-3-
30 yl)imidazo[1,2-a]pyridin-3-yl)-N-metyltiazol-2-amin,
4-(4-tert-butylfenyl)-N-(2-etyl-6-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-
yl)imidazo[1,2-a]pyridin-3-yl)-N-metyltiazol-2-amin,
N-(2-etyl-6-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)imidazo[1,2-a]pyridin-3-
yl)-4-(4-metoksyfenyl)-N-metyltiazol-2-amin,
35 N-(2-etyl-6-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)imidazo[1,2-a]pyridin-3-
yl)-N-metyl-4-(4-(trifluormetoksy)fenyl)tiazol-2-amin,

4-(3,4-difluorfenyl)-N-(2-etil-6-(1-(metylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)imidazo[1,2-a]pyridin-3-yl)-N-metyltaiazol-2-amin,
3-(4-(2-etil-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)-5,6-dihydropyridin-1(2H)-ylsulfonyl)propylacetat,
5 3-(4-(2-etil-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)-5,6-dihydropyridin-1(2H)-ylsulfonyl)propan-1-ol,
4-(2-etil-3-((4-(4-klorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)-3,6-dihydro-2H-tiopyran 1,1-dioksid,
N-(2-etil-6-(1-(metylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)imidazo[1,2-a]pyridin-3-yl)-5-fluor-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,
10 tert-butyl 4-(2-etil-3-((4-(4-fluorfenyl)tiazol-2-yl)(methyl)amino)imidazo[1,2-a]pyridin-6-yl)-3-hydroksypiperidin-1-karboksylat,
4-(2-etil-3-((4-(4-fluorfenyl)tiazol-2-yl)(methyl)amino)imidazo[1,2-a]pyridin-6-yl)-1-(metylsulfonyl)piperidin-3-ol,
15 N-(2-etil-6-(1-(metylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,
4-(4-tert-butylfenyl)-N-(2-etil-6-(1-(metylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)-N-metyltaiazol-2-amin,
N-(2-etil-6-(1-(metylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)-4-(4-metoksyfenyl)-N-metyltaiazol-2-amin,
20 4-(3,4-difluorfenyl)-N-(2-etil-6-(1-(metylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)-N-metyltaiazol-2-amin,
N-(2-etil-6-(1-(metylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)-N-metyl-4-(4-(trifluormetyl)fenyl)tiazol-2-amin,
25 N-(2-etil-6-(1-(metylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)-N-metyl-4-(4-(trifluormetoksy)fenyl)tiazol-2-amin,
N-(6-(1-(3-klorpropylsulfonyl)piperidin-4-yl)-2-etylimidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,
N-(6-(1-(3-(dimethylamino)propylsulfonyl)piperidin-4-yl)-2-etylimidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,
30 35 N-(2-etil-6-(1-(3-morfolinopropylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,
N-(2-etil-6-(1-(3-(pyrrolidin-1-yl)propylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,
N-(6-(1-(3-aminopropylsulfonyl)piperidin-4-yl)-2-etylimidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,

- N-(2-etyl-6-(1-(2-morfolinoethylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltiazol-2-amin,
4-(2-etyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-sulfonamid,
5 3-(4-(2-etyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-ylsulfonyl)propylacetat,
3-(4-(2-etyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-ylsulfonyl)propan-1-ol,
3-(4-(2-etyl-3-((5-fluor-4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-ylsulfonyl)propan-1-ol,
10 2-(2-((2-etyl-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)tiazol-4-yl)-5-fluorbenzonitril,
2-(2-((2-etyl-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)-5-metyltiazol-4-yl)-5-fluorbenzonitril,
15 N-(2-etyl-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)-4-(4-fluor-2-methylfenyl)-N-metyltiazol-2-amin,
4-(2-klor-4-fluorfenyl)-N-(2-etyl-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)-N-metyltiazol-2-amin,
4-(2,4-difluorfenyl)-N-(2-etyl-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-
20 a]pyridin-3-yl)-N-metyltiazol-2-amin,
N-(2-etyl-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N,5-dimetyltiazol-2-amin,
4-(4-fluorfenyl)-N-(2-etyl-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-
yl)-N-(d3-metyl)tiazol-2-amin,
25 4-(4-fluorfenyl)-N-(2-etyl-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-
yl)-N-(d3-metyl)-(d-tiazol-2)-amin,
metyl 2-((2-etyl-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-
yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-karboksylat,
1-(2-((2-etyl-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-
30 yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-yl)etanon,
N-(2-(2-((2-etyl-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-
yl)(metyl)amino)tiazol-4-yl)-5-fluorfenyl)acetamid,
(2-(2-((2-etyl-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-
yl)(metyl)amino)tiazol-4-yl)-5-fluorfenyl)metanol,
35 etyl 2-(4-(2-etyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-
yl)-5,6-dihydropyridin-1(2H)-yl)acetat,

etyl 2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)acetat,
2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)-1-(3-hydroksyazetidin-1-yl)etanon,
5 (R)-2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)-1-(3-hydroksypyrrolidin-1-yl)etanon,
(S)-2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)-1-(3-hydroksypyrrolidin-1-yl)etanon,
2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-
10 yl)piperidin-1-yl)-1-(3-(hydroksymetyl)azetidin-1-yl)etanon,
2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-
yl)piperidin-1-yl)-N,N-dimetylacetamid,
2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-
yl)piperidin-1-yl)-1-(pyrrolidin-1-yl)etanon,
15 (S)-1-(2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-
a]pyridin-6-yl)piperidin-1-yl)acetyl)pyrrolidin-3-karbonitril,
2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-
yl)piperidin-1-yl)-1-(3-(hydroksymetyl)pyrrolidin-1-yl)etanon,
4-((4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-
20 yl)piperidin-1-yl)methyl)-1,3-dioksolan-2-on,
2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-
yl)piperidin-1-yl)-N-(2-hydroksyethyl)-N-metylacetamid,
2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-
yl)piperidin-1-yl)-N-metoksy-N-metylacetamid,
25 N-(cyanometyl)-2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-
a]pyridin-6-yl)piperidin-1-yl)-N-metylacetamid,
5-((4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-
yl)piperidin-1-yl)methyl)oksazolidin-2-on,
2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-
30 yl)piperidin-1-yl)-N-(3-hydroksypropyl)acetamid,
1-(3,3-difluorazetidin-1-yl)-2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-
yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)etanon,
2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-
yl)piperidin-1-yl)acetamid,
35 1-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-
yl)piperidin-1-yl)-2-(pyrrolidin-1-yl)etanon,

1-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)-2-(methylamino)etanon,
1-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)-2-(3-hydroksyazetidin-1-yl)etanon,
5 2-(dimethylamino)-1-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)-imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)etanon,
3-(dimethylamino)-1-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)propan-1-on,
2-(3,3-difluorazetidin-1-yl)-1-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-
10 yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)etanon,
1-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)-3-(methylamino)propan-1-on,
1-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-
15 yl)piperidin-1-yl)-2-(3-fluorazetidin-1-yl)etanon,
1-(3-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-
yl)piperidin-1-yl)azetidin-1-yl)etanon,
5-brom-N-(2-ethyl-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)-4-(4-
fluorfenyl)-N-metyltaiazol-2-amin,
2-((2-ethyl-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-
20 yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-karbonitril,
2-((2-ethyl-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-
yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-karboksamid,
2-((2-ethyl-6-(4-(2-(3-hydroksyazetidin-1-yl)-2-oksoetyl)piperazin-1-yl)imidazo[1,2-
a]pyridin-3-yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-karbonitril,
25 2-((2-ethyl-6-(4-(2-(3-hydroksymetyl)azetidin-1-yl)-2-oksoetyl)piperazin-1-
yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-karbonitril,
2-(4-(3-((5-cyano-4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)-2-etyl)imidazo[1,2-
a]pyridin-6-yl)piperazin-1-yl)-N,N-dimetylacetamid,
2-((2-ethyl-6-(1-(2-(3-hydroksyazetidin-1-yl)-2-oksoetyl)piperidin-4-yl)imidazo[1,2-
30 a]pyridin-3-yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-karbonitril,
(R)-2-((2-ethyl-6-(1-(2-(3-hydroksypyrrolidin-1-yl)-2-oksoetyl)piperidin-4-
yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-karbonitril,
(S)-2-((2-ethyl-6-(1-(2-(3-hydroksypyrrolidin-1-yl)-2-oksoetyl)piperidin-4-
yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-karbonitril,
35 2-((2-ethyl-6-(1-(2-(3-hydroksymetyl)azetidin-1-yl)-2-oksoetyl)piperidin-4-
yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-karbonitril,

2-(4-(3-((5-cyano-4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)-2-etylimidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)-N,N-dimethylacetamid,
2-(4-(2-etyl-3-((4-(4-fluorfenyl)-5-(hydroksymetyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-1-(3-hydroksymetyl)azetidin-1-yl)etanon,
5 (2-((2-etyl-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-yl)metanol,
(2-((2-etyl-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)-4-(4-(trifluormetoksy)fenyl)tiazol-5-yl)metanol,
10 (2-((6-(1-(3-(dimethylamino)propylsulfonyl)piperidin-4-yl)-2-etylimidazo[1,2-a]pyridin-3-yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-yl),
(2-((2-etyl-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)-4-(4-(trifluormetyl)fenyl)tiazol-5-yl)metanol,
2-(4-(2-etyl-3-((4-(4-fluorfenyl)-5-(hydroksymetyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)-1-(pyrrolidin-1-yl)etanon,
15 2-(4-(2-etyl-3-((4-(4-fluorfenyl)-5-(hydroksymetyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)-1-(3-hydroksymetyl)azetidin-1-yl)etanon,
2-(dimethylamino)-1-(4-(2-etyl-3-((4-(4-fluorfenyl)-5-(hydroksymetyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)etanon,
20 1-(4-(2-etyl-3-((4-(4-fluorfenyl)-5-(hydroksymetyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)propan-1-on,
2-(4-(2-etyl-3-((4-(4-fluorfenyl)-5-(hydroksymetyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-N,N-dimethylacetamid,
25 2-(4-(2-etyl-3-((4-(4-fluorfenyl)-5-(hydroksymetyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)-1-(3-hydroksyazetidin-1-yl)etanon,
2-(4-(2-etyl-3-((4-(4-fluorfenyl)-5-(hydroksymetyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)-N,N-dimethylacetamid,
30 2-(4-(2-etyl-3-((4-(4-fluorfenyl)-5-(2,2,2-trifluoracetyl) tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-N,N-dimethylacetamid,
1-(2-((2-etyl-6-(1-(2-(3-hydroksyazetidin-1-yl)-2-oksoetyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-yl)-2,2,2-trifluoretanon,
35 1-(2-((2-etyl-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-yl)-2,2,2-trifluoretanon,
2-(2-((2-etyl-6-(piperazin-1-yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)-5-metyltaiazol-4-yl)-5-fluorbenzonitril,

2-(2-((2-etyl-6-(4-(2-(3-hydroksyazetidin-1-yl)-2-oksoetyl)piperazin-1-yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)-5-metyltiazol-4-yl)-5-fluorbenzonitril,
2-(4-(3-((4-(2-cyano-4-fluorfenyl)-5-metyltiazol-2-yl)(metyl)amino)-2-etyl)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-N-methylacetamid,
5 2-(2-((2-etyl-6-(4-(2-(3-fluorazetidin-1-yl)-2-oksoetyl)piperazin-1-yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)tiazol-4-yl)-5-fluorbenzonitril,
2-(2-((6-(4-(2-(3,3-difluorazetidin-1-yl)-2-oksoetyl)piperazin-1-yl)-2-etyl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)tiazol-4-yl)-5-fluorbenzonitril,
2-(2-((2-etyl-6-(4-(2-(3-hydroksyazetidin-1-yl)-2-oksoetyl)piperazin-1-yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)tiazol-4-yl)-5-fluorbenzonitril,
10 2-(2-((6-(4-(2-(azetidin-1-yl)-2-oksoetyl)piperazin-1-yl)-2-etyl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)tiazol-4-yl)-5-fluorbenzonitril,
2-(4-(3-((4-(2-cyano-4-fluorfenyl)tiazol-2-yl)(metyl)amino)-2-etyl)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-N,N-dimethylacetamid,
15 2-(4-(3-((4-(2-cyano-4-fluorfenyl)tiazol-2-yl)(metyl)amino)-2-etyl)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-N-methylacetamid,
2-(2-((2-etyl-6-(1-(2-(3-hydroksyazetidin-1-yl)-2-oksoetyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)tiazol-4-yl)-5-fluorbenzonitril,
2-(4-(3-((4-(2-cyano-4-fluorfenyl)tiazol-2-yl)(metyl)amino)-2-etyl)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)-N,N-dimethylacetamid,
20 2-(2-((2-etyl-6-(1-(2-(3-hydroksyazetidin-1-yl)-2-oksoetyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)-5-metyltiazol-4-yl)-5-fluorbenzonitril,
2-(5-((2-etyl-6-(1-(2-(3-hydroksyazetidin-1-yl)-2-oksoetyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)-1,2,4-tiadiazol-3-yl)-5-fluorbenzonitril,
25 2-(4-(2-(2-cyanoethyl)-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)-N,N-dimethylacetamid,
3-((4-(4-fluorfenyl)-5-(hydroksymethyl)tiazol-2-yl)(metyl)amino)-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-2-yl)propanitril,
30 3-((6-(1-(dimethylamino)-2-oksoethyl)piperidin-4-yl)-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-2-yl)propanamid,
N-(6-(3-aminoazetidin-1-yl)-2-etyl)imidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltiazol-2-amin,
2-(1-(2-etyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)azetidin-3-ylamino)-1-(3-hydroksyazetidin-1-yl)etanon,
35 N-(1-(2-etyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)azetidin-3-yl)-2-(3-hydroksyazetidin-1-yl)acetamid,

- 2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)etanol,
- N-(2-ethyl-6-morfolinoimidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltiazol-2-amin,
- 5 4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)-tiomorfolin 1,1-dioksid,
- 1-(3-((4-(4-klorfenyl)tiazol-2-yl)(metyl)amino)-2-etylimidazo[1,2-a]pyridin-6-yl)imidazolidin-2-on,
- 10 etyl 2-(3-(3-((4-(4-klorfenyl)tiazol-2-yl)(metyl)amino)-2-etylimidazo[1,2-a]pyridin-6-yl)-2-oksoimidazolidin-1-yl)acetat,
- 4-(4-klorfenyl)-N-metyl-N-(6-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-2-(2,2,2-trifluoretyl)imidazo[1,2-a]pyridin-3-yl)tiazol-2-amin,
- 2-(2-((2-ethyl-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)-4-(4-fluorfenyl)tiazol-5-yl)acetonitril,
- 15 2-etyl-N-(4-(4-fluorfenyl)pyrimidin-2-yl)-N-metyl-6-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)imidazo[1,2-a]pyridin-3-amin,
- 3-(4-klorfenyl)-N-(2-etyl-6-(4-(methylsulfonyl)piperazin-1-yl)imidazo[1,2-a]pyridin-3-yl)-N-metyl-1,2,4-tiadiazol-5-amin,
- N-(2-etyl-6-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)imidazo[1,2-a]pyridin-3-yl)-3-(4-fluorfenyl)-N-metyl-1,2,4-oksadiazol-5-amin,
- 20 2-(4-(2-etyl-3-((3-(4-fluorfenyl)-1,2,4-tiadiazol-5-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)-5,6-dihydropyridin-1(2H)-yl)-N,N-dimetylacetamid,
- 2-(4-(2-etyl-3-((3-(4-fluorfenyl)-1,2,4-tiadiazol-5-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)-N,N-dimetylacetamid,
- 25 N-(6-(4-((1H-imidazol-5-yl)metyl)piperazin-1-yl)-2-etylimidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltiazol-2-amin,
- N-(2-etyl-6-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)imidazo[1,2-a]pyridin-3-yl)-N-metyl-4-(4-(trifluormetyl)fenyl)tiazol-2-amin,
- N-cyklopropyl-2-(4-(2-etyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)acetamid,
- 30 5-((4-(2-etyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)metyl)-3-metyloksazolidin-2-on,
- (R)-5-((4-(2-etyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)metyl)oksazolidin-2-on,
- 35 (S)-5-((4-(2-etyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)metyl)oksazolidin-2-on,

4-((4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)metyl)oksazolidin-2-on,
 N-(2-ethyl-6-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)imidazo[1,2-a]pyridin-3-yl)-3-(4-fluorfenyl)-N-metyl-1,2,4-tiadiazol-5-amin,
 5 1-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)propan-1,2-dion,
 5-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-karbonyl)pyrrolidin-2-on,
 (1-aminocyklopropyl)(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)metanon,
 10 (S)-1-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-2-hydroksypropan-1-on,
 2-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-2-oksoacetamid,
 15 1-benzyl-4-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-karbonyl)pyrrolidin-2-on,
 3-(3-((4-(4-klorfenyl)tiazol-2-yl)(metyl)amino)-2-etylimidazo[1,2-a]pyridin-6-yl)oksazolidin-2-on,
 2-(2-ethyl-3-((4-(4-klorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)-1-[1,2]tiazinan-1,1-dioksid,
 20 4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)-N-(tiofen-2-yl)-5,6-dihydropyridin-1(2H)-karboksamid,
 4-(4-klorfenyl)-N-(2-ethyl-6-(1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)imidazo[1,2-a]pyridin-3-yl)-N-metyltaiazol-2-amin,
 25 4-(4-klorfenyl)-N-(2-ethyl-6-(1-(trifluormethylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)imidazo[1,2-a]pyridin-3-yl)-N-metyltaiazol-2-amin,
 1-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-4-ol,
 2-(4-(3-((4-(4-klorfenyl)tiazol-2-yl)(metyl)amino)-2-etylimidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)etanol,
 30 4-(2-ethyl-3-((4-(4-klorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)-tiomorfolin-1,1-dioksid,
 tert-butyl 4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)-5,6-dihydropyridin-1(2H)-karboksylat,
 35 1-(4-(2-ethyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)propan-1-on,

- N-(2-etil-6-(piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,
- N-(6-(1-benzylpiperidin-4-yl)-2-etylimidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,
- 5 N-(2-etil-6-(1-isopropylpiperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,
- tert-butyl 4-(2-etil-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-karboksylat,
- N-(6-(3,6-dihydro-2H-pyran-4-yl)-2-etylimidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,
- 10 N-(6-(3,6-dihydro-2H-pyran-4-yl)-2-etylimidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,
- 4-(4-klorfenyl)-N-(6-(3,6-dihydro-2H-pyran-4-yl)-2-etylimidazo[1,2-a]pyridin-3-yl)-N-metyltaiazol-2-amin,
- (2-(4-(2-etil-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)-4,5-dihydrooksazol-5-yl)metanol,
- 15 2-(4-(2-etil-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperidin-1-yl)-1-(3-hydroksypyrrolidin-1-yl)etanon,
- 2-(2-((2-etil-6-(1-(methylsulfonyl)piperidin-4-yl)imidazo[1,2-a]pyridin-3-yl)(metyl)amino)tiazol-4-yl)-5-fluorfenol,
- tert-butyl 4-(3-((3-(4-klorfenyl)-1,2,4-tiadiazol-5-yl)(metyl)amino)-2-etylimidazo[1,2-a]pyridin-6-yl)piperazin-1-karboksylat,
- 20 N-(6-(4-((1H-imidazol-2-yl)metyl)piperazin-1-yl)-2-etylimidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,
- cyklopropyl(4-(2-etil-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)metanon,
- 25 etyl 2-(4-(2-etil-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)piperazin-1-yl)-2-oksoacetat,
- [6-(1,1-diokso-isotiazolidin-2-yl)-2-etil-imidazo[1,2-a]pyridin-3-yl]-[4-(4-fluorfenyl)-tiazol-2-yl]-metyl-amin,
- tert-butyl 4-(3-((4-(4-klorfenyl)tiazol-2-yl)(metyl)amino)-2-etylimidazo[1,2-a]pyridin-6-yl)-5,6-dihydropyridin-1(2H)-karboksylat,
- 30 4-(4-klorfenyl)-N-(6-(3,6-dihydro-2H-tiopyran-4-yl)-2-etylimidazo[1,2-a]pyridin-3-yl)-N-metyltaiazol-2-amin,
- N-(6-(4,4-difluorpiperidin-1-yl)-2-etylimidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,
- 35 N-(6-(1-(3-klorpropylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl)-2-etylimidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,

tert-butyl 4-(3-((4-(4-klorfenyl)tiazol-2-yl)(metyl)amino)-2-etylimidazo[1,2-a]pyridin-6-yl)piperazin-1-karboksylat,

N-(6-(1-(cykloheksylmetyl)piperidin-4-yl)-2-etylimidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,

5 N-(2-etyl-6-(5-metyl-4,5-dihydrooksazol-2-yl)imidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,

N-(2-etyl-6-(4-metyl-4,5-dihydrooksazol-2-yl)imidazo[1,2-a]pyridin-3-yl)-4-(4-fluorfenyl)-N-metyltaiazol-2-amin,

2-((2-etyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)-4,5-dihydrooksazol-4-karboksylsyre,

(2-(2-etyl-3-((4-(4-fluorfenyl)tiazol-2-yl)(metyl)amino)imidazo[1,2-a]pyridin-6-yl)-4,5-dihydrooksazol-4-yl)metanol og

4-(4-klorfenyl)-N-(6-(4,5-dihydrooksazol-2-yl)-2-etylimidazo[1,2-a]pyridin-3-yl)-N-metyltaiazol-2-amin.

15

15. Farmasøytisk preparat omfattende en farmasøytisk akseptabel bærer og en farmasøytisk effektiv mengde av en forbindelse ifølge hvilket som helst av kravene 1-14.

20

16. Farmasøytisk preparat ifølge krav 15, omfattende et ytterligere terapeutisk middel.

25

17. Forbindelse eller farmasøytisk akseptabelt salt derav ifølge hvilket som helst av kravene 1-14 eller et farmasøytisk preparat ifølge krav 15 eller 16, for anvendelse i medisin.

30

18. Forbindelse eller farmasøytisk akseptabelt salt derav ifølge hvilket som helst av kravene 1-14 eller et farmasøytisk preparat ifølge krav 15 eller 16, for anvendelse ved behandling av fibrotiske sykdommer, proliferative sykdommer, inflammatoriske sykdommer, autoimmune sykdommer, respiratoriske sykdommer, kardiovaskulære sykdommer, neurodegenerative sykdommer, dermatologiske lidelser og/eller unormal angiogenese-assoserte sykdommer.

35

19. Forbindelse eller farmasøytisk akseptabelt salt derav eller farmasøytisk preparat for anvendelse ifølge krav 18, hvor nevnte forbindelse eller farmasøytisk akseptable salt derav eller farmasøytiske preparat blir administrert i kombinasjon

med et ytterligere terapeutisk middel.

20. Farmasøytiske preparatet ifølge krav 16 eller forbindelse eller farmasøytisk akseptabelt salt derav eller farmasøytisk preparat for anvendelse ifølge krav 19, hvor det ytterligere terapeutiske middel er for behandling av fibrotiske sykdommer, proliferative sykdommer, inflammatoriske sykdommer, autoimmune sykdommer, respiratoriske sykdommer, kardiovaskulære sykdommer, neurodegenerative sykdommer, dermatologiske lidelser og/eller unormal angiogenese-assosierete sykdommer.